An open-label Phase 2 study is designed to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype.
Age
18–68
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2
Chronic kidney disease with persistent albuminuria
You may not be if
Organ or bone marrow transplantation
History of active cancer within past 2 years, except for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer
Conditions that may alter drug absorption, e.g., history of bariatric surgery
Type I diabetes
Pregnant or currently nursing
Clareo Health | A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
